GPhA appoints board of directors for 2013
ORLANDO, Fla. — The Generic Pharmaceutical Association re-elected its chairman from last year and appointed a new board of directors for 2013 whose members run from A to Z — as in Amneal to Zydus.
"We are grateful for the vision and support of the 2012 board of directors, and we are excited to move ahead with our chairman and our 2013 board," GPhA president and CEO Ralph Neas said. "In a time of enormous change and growth for our industry, leadership is critical."
Mylan North America president Tony Mauro was elected as chairman for a second year, having served as chairman in 2012. The GPhA’s rules stipulate that a chairman or chairwoman can be elected for up to two one-year terms.
"I’m honored to have been elected to serve a second term as chairman of GPhA’s board of directors," Mauro said. "The role that the generics industry plans in providing sustainable healthcare solutions for patients in the United States and around the world has never been more important."
The board for this year includes Don DeGolyer, president and CEO of Sandoz US, elected as vice chairman; Craig Wheeler, president and CEO of Momenta Pharmaceuticals, elected as secretary treasurer; Debra Barrett, SVP global government affairs and public policy of Teva Pharmaceuticals; Carole Ben-Maimon, president for global pharmaceuticals of Impax Labs; Doug Boothe, EVP and general manager of Perrigo Pharmaceuticals; Chuck Caprariello, VP corporate communications and government affairs of Ranbaxy; John Ducker, president and CEO of Fresnius-Kabi USA; Jeffrey Glazer, president and CEO of Heritage Pharmaceuticals; Charlie Mayr, global chief communications officer of Actavis; Thomas Moore, U.S. president of Hospira; Chirag Patel, CEO of Amneal Pharmaceuticals; Joseph Renner, president and CEO of Zydus Pharmaceuticals USA; George Stevenson, president and CEO of Kremers-Urban Pharmaceuticals; and Jeff Watson, president of Apotex.
Kerr Drug completes chainwide implementation of PDX pharmacy system
RALEIGH, N.C. — Kerr Drug has rolled out the PDX Enterprise Pharmacy System chainwide, the retail pharmacy chain said.
Kerr said the system would help it focus on "the future of pharmacy," with increased prescription volume and higher patient care requirements.
"We are really investing heavily in our infrastructure," Kerr Drug VP and CIO Joey Dorsett said. "As a regional chain, it hasn’t always been possible to be the first adopters of all the innovative technologies, but it is non-negotiable that we provide pharmacy services with the best of the best. With PDX, we are able to deliver cutting-edge solutions that improve patients’ lives through better technology."
The PDX system features integrated, centralized pharmacy records, improves work processes and efficiencies and helps to lower labor costs through separation of tasks by the pharmacists and technicians, Kerr said.
The company said the completion of the PDX platform alsowould complement its mobile pharmacy system, allowing smartphone users to refill prescriptions, receive pickup and dosage reminders and retrieve their prescription history via mobile.
"Kerr delivers cutting-edge solutions to improve our patients’ health and make their lives easier," Kerr president and CEO Tony Civello said. "The mobile option allows patients to convert their phones into medical wallets … to access a wide range of our pharmacy services."
Three-quarters of Americans never receive skin exams, perform mole self checks, survey finds
IRVINGTON, N.Y. — Less than one-quarter of American adults have ever had a skin check by a dermatologist despite rising rates of skin cancer, according to a new survey.
The survey, conducted online by Harris Interactive on behalf of Mela Sciences, a company that makes a device for use by doctors to detect potentially dangerous skin lesions, polled 2,109 American adults between Jan. 29 and 31, finding that only 23% of Americans perform monthly mole self-checks, while 37% think they are not at risk from skin cancer, despite industry statistics indicating that 1-in-5 will develop skin cancer annually. At the same time, while 85% stated correctly that moles are often precursors to melanoma, 20% said they "are simply beauty marks."
"While many forms of cancer are on the decline, melanoma continues to rise and, in fact, is the leading cause of cancer death in women ages 25 to 30 years and second only to breast cancer in women ages 30 to 34 years," Mela Sciences president and CEO Joseph Gulfo said. "We have a tremendous opportunity to spread awareness and change the course of the disease by advocating for the detection of melanoma at its most curable stage, and with this survey, we’ll draw attention to the importance of annual skin checks in the fight against melanoma."
The company markets MelaFind, a diagnostic tool approved by the Food and Drug Administration for detecting melanoma at its most curable stage, when it is limited to the outermost layer of the skin.